Findings from a study published May 3, 2025, in The Lancet demonstrate that oral gepotidacin is a noninferior and safe alternative to ceftriaxone plus azithromycin for uncomplicated urogenital gonorrhea.
APhA staff
Dismissing patient, family, and caregiver concerns is the biggest threat to patient safety, according to ECRI. The organization said that time and resource constraints are making it increasingly difficult for health care providers to address patient concerns.
Preliminary data suggest that CDC’s recommendation that all qualified persons 6 months and older receive a 2024–2025 COVID-19 vaccination was an effective move.
On February 4, 2025, FDA approved Onapgo (apomorphine hydrochloride), a wearable infusion device, available soon in the United States for adults with advanced Parkinson’s disease.
On January 6, 2025, FDA published new draft guidance aimed at helping improve the accuracy and performance of pulse oximeters.